Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas
Abstract Background This study aimed at applying the restricted mean survival time difference (rmstD) as an absolute outcome measure in a network meta-analysis and comparing the results with those obtained using hazard ratios (HR) from the individual patient data (IPD) network meta-analysis (NMA) on...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Systematic Reviews |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13643-019-0984-x |
id |
doaj-bd4ac6b0061a4d9ba8ab42173013a00c |
---|---|
record_format |
Article |
spelling |
doaj-bd4ac6b0061a4d9ba8ab42173013a00c2020-11-25T03:01:00ZengBMCSystematic Reviews2046-40532019-04-018111210.1186/s13643-019-0984-xIndividual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomasC. Petit0P. Blanchard1JP. Pignon2B. Lueza3Gustave Roussy, Service de Biostatistiques et d’Épidémiologie and Ligue Nationale Contre le Cancer Meta-Analysis Platform, Université Paris-SaclayGustave Roussy, Service de Biostatistiques et d’Épidémiologie and Ligue Nationale Contre le Cancer Meta-Analysis Platform, Université Paris-SaclayGustave Roussy, Service de Biostatistiques et d’Épidémiologie and Ligue Nationale Contre le Cancer Meta-Analysis Platform, Université Paris-SaclayGustave Roussy, Service de Biostatistiques et d’Épidémiologie and Ligue Nationale Contre le Cancer Meta-Analysis Platform, Université Paris-SaclayAbstract Background This study aimed at applying the restricted mean survival time difference (rmstD) as an absolute outcome measure in a network meta-analysis and comparing the results with those obtained using hazard ratios (HR) from the individual patient data (IPD) network meta-analysis (NMA) on the role of chemotherapy for nasopharyngeal carcinoma (NPC) recently published by the MAC-NPC collaborative group (Meta-Analysis of Chemotherapy [CT] in NPC). Patients and methods Twenty trials (5144 patients) comparing radiotherapy (RT) with or without CT in non-metastatic NPC were included. Treatments were grouped in seven categories: RT alone (RT), induction CT followed by RT (IC-RT), RT followed by adjuvant CT (RT-AC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed by CRT (IC-CRT), and CRT followed by AC (CRT-AC). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival and locoregional control. The rmstD was estimated at t* = 10 years in each trial. Random-effect frequentist NMA models were applied. P score was used to rank treatments. Heterogeneity and inconsistency were evaluated. Results The three treatments that had the highest effect on OS with rmstD were CRT-AC, IC-CRT, and CRT (respective P scores of 92%, 72%, and 64%) compared to CRT-AC, CRT, and IC-CRT when using HR (respective P scores of 96%, 71%, and 63%). Of the 32 HR and rmstD analyzed, 5 had a different interpretation, 3 with a direction change (different direction of treatment effect) and 2 with a change in significance (same direction but a change in statistical significance). Results for secondary endpoints were overall in agreement. Conclusion The use of either HR or rmstD impacts the results of NMA. Given the sensitivity of HR to non-proportional hazards, this finding could have implications in terms of meta-analysis methodology.http://link.springer.com/article/10.1186/s13643-019-0984-xHazard ratioSurvival analysisRestricted mean survival time differenceNetwork meta-analysisNasopharyngeal carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
C. Petit P. Blanchard JP. Pignon B. Lueza |
spellingShingle |
C. Petit P. Blanchard JP. Pignon B. Lueza Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas Systematic Reviews Hazard ratio Survival analysis Restricted mean survival time difference Network meta-analysis Nasopharyngeal carcinoma |
author_facet |
C. Petit P. Blanchard JP. Pignon B. Lueza |
author_sort |
C. Petit |
title |
Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas |
title_short |
Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas |
title_full |
Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas |
title_fullStr |
Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas |
title_full_unstemmed |
Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas |
title_sort |
individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? a case study on locoregionally advanced nasopharyngeal carcinomas |
publisher |
BMC |
series |
Systematic Reviews |
issn |
2046-4053 |
publishDate |
2019-04-01 |
description |
Abstract Background This study aimed at applying the restricted mean survival time difference (rmstD) as an absolute outcome measure in a network meta-analysis and comparing the results with those obtained using hazard ratios (HR) from the individual patient data (IPD) network meta-analysis (NMA) on the role of chemotherapy for nasopharyngeal carcinoma (NPC) recently published by the MAC-NPC collaborative group (Meta-Analysis of Chemotherapy [CT] in NPC). Patients and methods Twenty trials (5144 patients) comparing radiotherapy (RT) with or without CT in non-metastatic NPC were included. Treatments were grouped in seven categories: RT alone (RT), induction CT followed by RT (IC-RT), RT followed by adjuvant CT (RT-AC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed by CRT (IC-CRT), and CRT followed by AC (CRT-AC). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival and locoregional control. The rmstD was estimated at t* = 10 years in each trial. Random-effect frequentist NMA models were applied. P score was used to rank treatments. Heterogeneity and inconsistency were evaluated. Results The three treatments that had the highest effect on OS with rmstD were CRT-AC, IC-CRT, and CRT (respective P scores of 92%, 72%, and 64%) compared to CRT-AC, CRT, and IC-CRT when using HR (respective P scores of 96%, 71%, and 63%). Of the 32 HR and rmstD analyzed, 5 had a different interpretation, 3 with a direction change (different direction of treatment effect) and 2 with a change in significance (same direction but a change in statistical significance). Results for secondary endpoints were overall in agreement. Conclusion The use of either HR or rmstD impacts the results of NMA. Given the sensitivity of HR to non-proportional hazards, this finding could have implications in terms of meta-analysis methodology. |
topic |
Hazard ratio Survival analysis Restricted mean survival time difference Network meta-analysis Nasopharyngeal carcinoma |
url |
http://link.springer.com/article/10.1186/s13643-019-0984-x |
work_keys_str_mv |
AT cpetit individualpatientdatanetworkmetaanalysisusingeitherrestrictedmeansurvivaltimedifferenceorhazardratiosisthereadifferenceacasestudyonlocoregionallyadvancednasopharyngealcarcinomas AT pblanchard individualpatientdatanetworkmetaanalysisusingeitherrestrictedmeansurvivaltimedifferenceorhazardratiosisthereadifferenceacasestudyonlocoregionallyadvancednasopharyngealcarcinomas AT jppignon individualpatientdatanetworkmetaanalysisusingeitherrestrictedmeansurvivaltimedifferenceorhazardratiosisthereadifferenceacasestudyonlocoregionallyadvancednasopharyngealcarcinomas AT blueza individualpatientdatanetworkmetaanalysisusingeitherrestrictedmeansurvivaltimedifferenceorhazardratiosisthereadifferenceacasestudyonlocoregionallyadvancednasopharyngealcarcinomas |
_version_ |
1724695575628087296 |